PEL

PEL(Piramal Enterprises Limited)

 22.09.2022 - EMKAY On PEL Maintain Buy CMP 969.5 Target 1360
16.09.2022 - Motilal Oswal on PEL Maintain Buy CMP 966 Target 1320
01.09.2022 - Jefferies on PEL Maintain Buy CMP 1077 Target 1250
01.08.2022 - Jefferies on PEL Maintain Buy CMP 1754 Target 2120
21.06.2022 - CLSA on PEL Maintain Buy CMP 1614 Target 2250
27.05.2022 - CLSA on PEL Maintain Buy CMP 1646.5 Target 2330
21.03.2022 - CITI on PEL Maintain Buy CMP 2236 Target 3180
03.03.2022 - CLSA on PEL Upgrade Buy CMP 2080 Target 2800(PREVTGT 2850)
11.02.2022 - CLSA on PEL Maintain Outperform CMP 2496 Target 2850
11.02.2022 - CITI on PEL Maintain Buy CMP 2496 Target 3180

CLSA ON PIRAMAL ENT : 01.09.2021

* Financial Services On A Different Path, Long Revenue Stream For Pharma
* It Is A Top-three Lender To The Real Estate Segment
* DHFL AcqN Is Expected To Enlarge Its Loan Book, Improve Return On Equity
* Should See An 18% FY21-24 EBITDA CAGR For Its Pharma Business
* INITIATE OUTPERFORM TARGET: 2,960